Business · 27/11/2024Updated: 10/17/2026 · 1 min read
FDA Announces Draft Guidance on Ovarian Toxicity in Premenopausal Adults During Oncologic Drug Development
Summary
The FDA has released a draft guidance for industry on assessing ovarian toxicity in premenopausal adults participating in cancer clinical trials, aiming to inform decision-making on anti-cancer treatments.